There are 2789 resources available
1284P - Sitravatinib + tislelizumab in patients with anti-PD-(L)1 refractory/resistant metastatic NSCLC
Presenter: Bo Gao
Session: ePoster Display
1285P - Final analysis of TORG1936/AMBITIOUS: Phase II study of atezolizumab for pretreated non-small cell lung cancer with idiopathic interstitial pneumonia
Presenter: Yuki Sato
Session: ePoster Display
1286P - Senescent immune phenotype (SIP) status predicts resistance to immune checkpoint blockers (ICB) among CMV+ advanced non-small cell lung cancer (aNSCLC) patients
Presenter: Marie Naigeon
Session: ePoster Display
1209P - RELAY, ramucirumab plus erlotinib (RAM+ERL) in untreated metastatic EGFR-mutant NSCLC (EGFR+NSCLC): Association between TP53 status and clinical outcome
Presenter: Makoto Nishio
Session: ePoster Display
1210P - Preclinical and preliminary clinical investigations of furmonertinib in NSCLC with EGFR exon 20 insertions (20ins)
Presenter: Baohui Han
Session: ePoster Display
1211P - Indirect comparison of mobocertinib and standard of care in platinum-pretreated patients with NSCLC with EGFR exon 20 insertion
Presenter: Sai-Hong Ou
Session: ePoster Display
1212P - Afatinib for the treatment of NSCLC with uncommon EGFR mutations: An updated database of 1023 cases
Presenter: James Yang Yang
Session: ePoster Display
1213P - Clinical utility of liquid biopsy for the early diagnosis of EGFR mutant advanced lung cancer in a real-life setting (CLEAR)
Presenter: Rami Nassabein
Session: ePoster Display
1214P - High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from a phase II multicenter study, POSITION20
Presenter: Fenneke Zwierenga
Session: ePoster Display
1215P - EGFR-mutated squamous cell lung cancer and its association with outcomes
Presenter: Yang Xia
Session: ePoster Display